"Chesapeake Urology is the largest, fully-integrated urology practice in Maryland and the Mid-Atlantic region, providing a comprehensive array of urologic services to patients. Our staff of more than 800 professionals, including more than 80 urologists and fellowship-trained specialists, focus on what’s most important to patients – superior and personalized care, an innovative approach to the most advanced diagnostics, leading-edge treatments, and clinical trials, as well as positive outcomes. At Chesapeake Urology, we’re dedicated to providing the most personal care for life’s most personal issues."

During the past decade, Chesapeake Urology Research Associates conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 6 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 6 clinical trials were completed. i.e. 46.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chesapeake Urology Research Associates" #1 sponsor was "GTx" with 3 trials, followed by "Urotronic Inc." with 3 trials sponsored, "Boston Scientific Corporation" with 2 trials sponsored, "Solace Therapeutics, Inc." with 2 trials sponsored and "UroGen Pharma Ltd." with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chesapeake Urology Research Associates" #1 collaborator was "ClinLogix. LLC" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator, "Patient-Centered Outcomes Research Institute" with 1 trials as a collaborator and "TesoRx Pharma, LLC" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Chesapeake Urology Research Associates" are "Stress Urinary Incontinence" (6 trials), "Bladder Cancer" (5 trials), "Non-muscle Invasive Bladder Cancer" (3 trials), "Enteric Hyperoxaluria" (2 trials) and "Urethral Stricture" (2 trials). Many other conditions were trialed in "Chesapeake Urology Research Associates" in a lesser frequency.

Most popular intervention types in "Chesapeake Urology Research Associates" are "Drug" (13 trials), "Device" (6 trials), "Biological" (3 trials), "Combination Product" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "GTx-024" (2 trials), "UGN-102" (2 trials), "Vesair Balloon" (2 trials) and "ALLN-177" (1 trials). Other intervention names were less common.

The vast majority of trials in "Chesapeake Urology Research Associates" are 14 trials for "All" genders, 8 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Chesapeake Urology Research Associates". undefined are not yet recruiting, 2 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Chesapeake Urology Research Associates, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Chesapeake Urology Research Associates, 4 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 7 trials that are defined as “Not Applicable".